Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRMT7-EXOC4

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRMT7-EXOC4
	FusionPDB ID: 68939
	FusionGDB2.0 ID: 68939
		Hgene	Tgene
	Gene symbol	PRMT7	EXOC4
	Gene ID	54496	60412
	Gene name	protein arginine methyltransferase 7	exocyst complex component 4
	Synonyms	SBIDDS	SEC8\|SEC8L1\|Sec8p
	Cytomap	16q22.1	7q33
	Type of gene	protein-coding	protein-coding
	Description	protein arginine N-methyltransferase 7[Myelin basic protein]-arginine N-methyltransferase PRMT7histone-arginine N-methyltransferase PRMT7	exocyst complex component 4SEC8-like 1exocyst complex component Sec8
	Modification date	20200320	20200320
	UniProtAcc	.	Q96A65 Main function of 5'-partner protein: FUNCTION: Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. {ECO:0000250}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000339507, ENST00000348497, ENST00000441236, ENST00000449359, ENST00000564441,	ENST00000460346, ENST00000393161, ENST00000541309, ENST00000545148, ENST00000253861, ENST00000539845,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 5 X 4=80	35 X 25 X 10=8750
	# samples	4	39
	** MAII score	log2(4/80*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(39/8750*10)=-4.48773698785744 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRMT7 [Title/Abstract] AND EXOC4 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRMT7 [Title/Abstract] AND EXOC4 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PRMT7(68380183)-EXOC4(133580352), # samples:2
Anticipated loss of major functional domain due to fusion event.	PRMT7-EXOC4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-EXOC4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-EXOC4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-EXOC4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PRMT7	GO:0016571	histone methylation	15494416
Hgene	PRMT7	GO:0018216	peptidyl-arginine methylation	15044439

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:68380183/chr7:133580352)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRMT7 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across EXOC4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000449359	PRMT7	chr16	68380183	+	ENST00000253861	EXOC4	chr7	133580352	+	3590	1168	61	2358	765
ENST00000449359	PRMT7	chr16	68380183	+	ENST00000539845	EXOC4	chr7	133580352	+	2418	1168	61	2358	765
ENST00000441236	PRMT7	chr16	68380183	+	ENST00000253861	EXOC4	chr7	133580352	+	4295	1873	766	3063	765
ENST00000441236	PRMT7	chr16	68380183	+	ENST00000539845	EXOC4	chr7	133580352	+	3123	1873	766	3063	765
ENST00000348497	PRMT7	chr16	68380183	+	ENST00000253861	EXOC4	chr7	133580352	+	4223	1801	766	2991	741
ENST00000348497	PRMT7	chr16	68380183	+	ENST00000539845	EXOC4	chr7	133580352	+	3051	1801	766	2991	741
ENST00000339507	PRMT7	chr16	68380183	+	ENST00000253861	EXOC4	chr7	133580352	+	4443	2021	764	3211	815
ENST00000339507	PRMT7	chr16	68380183	+	ENST00000539845	EXOC4	chr7	133580352	+	3271	2021	764	3211	815

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000449359	ENST00000253861	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.002868724	0.9971312
ENST00000449359	ENST00000539845	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.01093277	0.98906726
ENST00000441236	ENST00000253861	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.002816789	0.99718314
ENST00000441236	ENST00000539845	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.009519685	0.99048036
ENST00000348497	ENST00000253861	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.001876046	0.99812394
ENST00000348497	ENST00000539845	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.007518487	0.9924816
ENST00000339507	ENST00000253861	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.003184307	0.99681574
ENST00000339507	ENST00000539845	PRMT7	chr16	68380183	+	EXOC4	chr7	133580352	+	0.009334815	0.9906652

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRMT7-EXOC4

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PRMT7	chr16	68380183	EXOC4	chr7	133580352	1168	369	QDRTDRYVQALRTSTIIVEKTVQDLL
PRMT7	chr16	68380183	EXOC4	chr7	133580352	1801	345	QDRTDRYVQALRTSTIIVEKTVQDLL
PRMT7	chr16	68380183	EXOC4	chr7	133580352	1873	369	QDRTDRYVQALRTSTIIVEKTVQDLL
PRMT7	chr16	68380183	EXOC4	chr7	133580352	2021	419	QDRTDRYVQALRTSTIIVEKTVQDLL

Top

Potential FusionNeoAntigen Information of PRMT7-EXOC4 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PRMT7-EXOC4_68380183_133580352.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:01	QALRTSTI	0.9963	0.7287	8	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A30:08	RTSTIIVEK	0.999	0.6431	11	20
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B14:02	VQALRTSTI	0.9898	0.8577	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B14:01	VQALRTSTI	0.9898	0.8577	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:02	QALRTSTII	0.9777	0.5808	8	17
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A02:13	ALRTSTIIV	0.975	0.6358	9	18
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A30:08	ALRTSTIIV	0.966	0.7552	9	18
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B48:01	VQALRTSTI	0.9544	0.535	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B08:09	VQALRTSTI	0.8859	0.635	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B13:02	VQALRTSTI	0.8646	0.7327	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B13:01	VQALRTSTI	0.5361	0.9756	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B52:01	VQALRTSTI	0.3156	0.9889	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:08	QALRTSTI	0.9904	0.5317	8	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B15:04	VQALRTSTI	0.8894	0.9203	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B14:03	VQALRTSTI	0.7989	0.8342	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:07	VQALRTSTI	0.3328	0.9765	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B27:14	LRTSTIIVEK	0.9994	0.8358	10	20
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B73:01	DRYVQALRTS	0.9822	0.8094	4	14
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:13	QALRTSTI	0.9967	0.5077	8	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:14	QALRTSTI	0.9931	0.7368	8	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B51:21	QALRTSTI	0.9873	0.6761	8	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A30:01	RTSTIIVEK	0.9991	0.792	11	20
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A02:03	ALRTSTIIV	0.9963	0.6155	9	18
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A30:01	ALRTSTIIV	0.9698	0.8572	9	18
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B15:73	VQALRTSTI	0.9299	0.8255	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B15:30	VQALRTSTI	0.8691	0.8974	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-B39:02	VQALRTSTI	0.6044	0.9097	7	16
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	HLA-A30:01	ALRTSTIIVEK	0.9934	0.8422	9	20

Top

Potential FusionNeoAntigen Information of PRMT7-EXOC4 in HLA II

PRMT7-EXOC4_68380183_133580352.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0403	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0403	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0405	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0405	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0409	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0409	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0411	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0411	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0424	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0424	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0429	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0429	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0430	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0430	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0439	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0439	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0441	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0441	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0444	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0445	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0445	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0446	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0446	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0448	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0448	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0449	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0452	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0452	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0457	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0457	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0459	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0459	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0460	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0460	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0462	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0462	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0467	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0467	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0467	ALRTSTIIVEKTVQD	9	24
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0471	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0471	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0477	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0477	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0483	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0483	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0484	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0484	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0485	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0485	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0487	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0487	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0488	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0488	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0489	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0489	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0491	LRTSTIIVEKTVQDL	10	25
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-0491	RTSTIIVEKTVQDLL	11	26
PRMT7-EXOC4	chr16	68380183	chr7	133580352	2021	DRB1-1221	DRYVQALRTSTIIVE	4	19

Top

Fusion breakpoint peptide structures of PRMT7-EXOC4

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10850	YVQALRTSTIIVEK	PRMT7	EXOC4	chr16	68380183	chr7	133580352	2021

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRMT7-EXOC4

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	10850	YVQALRTSTIIVEK	-7.9962	-8.1096
HLA-B14:02	3BVN	10850	YVQALRTSTIIVEK	-5.70842	-6.74372
HLA-B52:01	3W39	10850	YVQALRTSTIIVEK	-6.83737	-6.95077
HLA-B52:01	3W39	10850	YVQALRTSTIIVEK	-4.4836	-5.5189
HLA-A11:01	4UQ2	10850	YVQALRTSTIIVEK	-10.0067	-10.1201
HLA-A11:01	4UQ2	10850	YVQALRTSTIIVEK	-9.03915	-10.0745
HLA-A24:02	5HGA	10850	YVQALRTSTIIVEK	-6.56204	-6.67544
HLA-A24:02	5HGA	10850	YVQALRTSTIIVEK	-5.42271	-6.45801
HLA-B44:05	3DX8	10850	YVQALRTSTIIVEK	-7.85648	-8.89178
HLA-B44:05	3DX8	10850	YVQALRTSTIIVEK	-5.3978	-5.5112
HLA-A02:01	6TDR	10850	YVQALRTSTIIVEK	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PRMT7-EXOC4

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PRMT7-EXOC4	chr16	68380183	chr7	133580352	10	20	LRTSTIIVEK	CTGAGGACCAGCACAATCATTGTGGAGAAG
PRMT7-EXOC4	chr16	68380183	chr7	133580352	11	20	RTSTIIVEK	AGGACCAGCACAATCATTGTGGAGAAG
PRMT7-EXOC4	chr16	68380183	chr7	133580352	4	14	DRYVQALRTS	GATCGATACGTCCAGGCTCTGAGGACCAGC
PRMT7-EXOC4	chr16	68380183	chr7	133580352	7	16	VQALRTSTI	GTCCAGGCTCTGAGGACCAGCACAATC
PRMT7-EXOC4	chr16	68380183	chr7	133580352	8	16	QALRTSTI	CAGGCTCTGAGGACCAGCACAATC
PRMT7-EXOC4	chr16	68380183	chr7	133580352	8	17	QALRTSTII	CAGGCTCTGAGGACCAGCACAATCATT
PRMT7-EXOC4	chr16	68380183	chr7	133580352	9	18	ALRTSTIIV	GCTCTGAGGACCAGCACAATCATTGTG
PRMT7-EXOC4	chr16	68380183	chr7	133580352	9	20	ALRTSTIIVEK	GCTCTGAGGACCAGCACAATCATTGTGGAGAAG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PRMT7-EXOC4	chr16	68380183	chr7	133580352	10	25	LRTSTIIVEKTVQDL	CTGAGGACCAGCACAATCATTGTGGAGAAGACAGTTCAAGACCTC
PRMT7-EXOC4	chr16	68380183	chr7	133580352	11	26	RTSTIIVEKTVQDLL	AGGACCAGCACAATCATTGTGGAGAAGACAGTTCAAGACCTCCTG
PRMT7-EXOC4	chr16	68380183	chr7	133580352	4	19	DRYVQALRTSTIIVE	GATCGATACGTCCAGGCTCTGAGGACCAGCACAATCATTGTGGAG
PRMT7-EXOC4	chr16	68380183	chr7	133580352	9	24	ALRTSTIIVEKTVQD	GCTCTGAGGACCAGCACAATCATTGTGGAGAAGACAGTTCAAGAC

Top

Information of the samples that have these potential fusion neoantigens of PRMT7-EXOC4

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SARC	PRMT7-EXOC4	chr16	68380183	ENST00000339507	chr7	133580352	ENST00000253861	TCGA-DX-A7EF-01A

Top

Potential target of CAR-T therapy development for PRMT7-EXOC4

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRMT7-EXOC4

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRMT7-EXOC4

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)